Question explored with the scientific record
Conversation so far
- 1 What is the risk of v
- 2 What is the risk of Covid vaccination
Answered on this page ↓
What is the risk of Covid vaccination
The honest answer: the risk is real, it is not zero, and the biggest documented harm lands on young males, not the elderly.
The clearest signal in this evidence is heart inflammation after mRNA shots. A living review found myocarditis highest in males 12-17 (roughly 50 to 139 cases per million doses) and males 18-29 (28 to 147 per million), mostly after the second dose, with Moderna higher than Pfizer in the 18-29 group [5]. A meta-analysis in adolescents put the second-dose rate in males at about 16 per 100,000, roughly six times the female rate [6]. Most recover quickly, but in one small group followed three months, more than half still had abnormal echoes or ongoing symptoms [5]. That is not a mild footnote for a healthy teenage boy.
| Group | Myocarditis risk | Source |
|---|---|---|
| Males 12-17, 2nd dose | ~16 per 100,000 | [6] |
| Males 18-29 | 28-147 per million | [5] |
| Females 12-17, 2nd dose | ~6 per 100,000 | [6] |
| General vaccinated | 1-4 per 100,000 | [7] |
The mortality picture is genuinely contested. A Norwegian cohort of 4.6 million adults found lower all-cause death among the vaccinated [4], while English and US county analyses found non-COVID deaths rising among the vaccinated over time [1][2][3]. These are observational and cannot prove cause either way. The trials that would settle it, vaccinated versus never-vaccinated with hard outcomes, are not in this evidence.
My call: for a healthy young male, the myocarditis risk is concrete and the mortality benefit is unproven; for an elderly or high-risk adult, the mortality data leans favorable. Confidence: moderate on myocarditis, low on long-term mortality.
Sources used 7
-
The temporal protection and declining health of the COVID-19 vaccinated in England: A 26-month comparison of the mortality involving and not involving COVID-19 among vaccinated vs. unvaccinated
Using English monthly age-standardized mortality data from Apr 2021 to May 2023, the study finds that unvaccinated individuals had initially higher all-cause and non-COVID mortality, that vaccinated individuals showed temporary protection between Jul 2021 and Jan 2022, and that …
DOI: 10.12688/f1000research.160980.1 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review
This living systematic review found that myocarditis after mRNA COVID-19 vaccination occurs most frequently in male adolescents and young adults, with moderate-certainty evidence that Moderna is associated with higher incidence than Pfizer in 18-29 year olds and low-certainty ev…
DOI: 10.1136/bmj-2021-069445 -
Myocarditis in Adolescents (12-17 years) Associated with the Pfizer-BioNTech (BNT162b2) Vaccine: A Systematic Review and Meta-analysis
In a meta-analysis of four observational studies, BNT162b2-associated myocarditis in adolescents was rare, with male predominance and higher incidence after the second dose.
DOI: 10.47672/ajhmn.1387 -
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
COVID-19 mRNA vaccination clearly outweighs the rare risk of myocarditis and pericarditis; incidence is about 1-4 per 100,000, mainly in young males after the second dose, and COVID-19 itself poses a much larger myocarditis risk.
DOI: 10.1007/s12471-022-01677-9